FDAnews
www.fdanews.com/articles/187916-insys-buprenorphine-spray-draws-complete-response-letter

Insys Buprenorphine Spray Draws Complete Response Letter

August 7, 2018

The FDA issued Insys a complete response letter citing safety concerns over the company’s NDA for a buprenorphine sublingual spray indicated for moderate-to-severe acute pain.

The CRL followed an FDA advisory committee meeting in May that found the company demonstrated statistically significant efficacy data but noted concerns about the safety data.

Insys said it continues to believe that the drug-device combination could provide effective pain management and said it willassess the next steps in the context of the company’s overall mission.”

View today's stories